Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour [5]

Histopathology

Volumn 46, Issue 4, 2005, Pages 470-472

  Abdulkader, I ^a   Cameselle Teijeiro, J ^a   Forteza, J ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB; STEM CELL FACTOR;

ADULT; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL CELL OF CAJAL; LETTER; LIVER METASTASIS; LIVER RESECTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

EID: 17144412186     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02014.x     Document Type: Letter

References (11)

1. Dei Tos AP. The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. Virchows. Arch. 2003: 442; 421-428.
2. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002: 347; 472-480.
3. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol. Oncol. Res. 2003: 9; 13-19.
4. Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert. Opin. Pharmacother. 2003: 4; 869-874.
5. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001: 344; 1052-1056.
6. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003: 21; 4342-4349.
7. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001: 358; 1421-1423.
8. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 2002: 38; S60-S65.
9. Bumming P, Andersson J, Meis-Kindblom JM et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br. J. Cancer 2003: 89; 460-464.
10. Hogenauer C, Langner C, Lipp RW, Hofler G, Krejs GJ, Hinterleitner TA. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur. J. Gastroenterol. Hepatol. 2003: 15; 323-327.
11. Colecchia M, Diment J. Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST. Int. J. Surg. Pathol. 2003: 11; 119.